DIVALPROEX TABLET (ENTERIC-COATED)

Riik: Kanada

keel: inglise

Allikas: Health Canada

Toimeaine:

VALPROIC ACID (DIVALPROEX SODIUM)

Saadav alates:

SANIS HEALTH INC

ATC kood:

N03AG01

INN (Rahvusvaheline Nimetus):

VALPROIC ACID

Annus:

250MG

Ravimvorm:

TABLET (ENTERIC-COATED)

Koostis:

VALPROIC ACID (DIVALPROEX SODIUM) 250MG

Manustamisviis:

ORAL

Ühikuid pakis:

100

Retsepti tüüp:

Prescription

Terapeutiline ala:

MISCELLANEOUS ANTICONVULSANTS

Toote kokkuvõte:

Active ingredient group (AIG) number: 0112996001; AHFS:

Volitamisolek:

APPROVED

Loa andmise kuupäev:

2013-02-11

Toote omadused

Page 1 of 49
PRODUCT MONOGRAPH
Pr
DIVALPROEX
DIVALPROEX SODIUM ENTERIC-COATED TABLETS
125 MG, 250 MG AND 500 MG VALPROIC ACID (AS DIVALPROEX SODIUM)
HOUSE STANDARD
ANTIEPILEPTIC
SANIS HEALTH INC.
DATE OF REVISION:
333 CHAMPLAIN ST. SUITE 102
DIEPPE, NEW BRUNSWICK
JUNE 16, 2014
E1A 1P2
CONTROL NUMBER: 174536
Page 2 of 49
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.....................................................................
3
SUMMARY PRODUCT INFORMATION
...........................................................................................
3
INDICATIONS AND CLINICAL USE
.................................................................................................
3
CONTRAINDICATIONS
......................................................................................................................
4
WARNINGS AND
PRECAUTIONS
..................................................................................................
5
ADVERSE REACTIONS
....................................................................................................................
16
DRUG INTERACTIONS
.....................................................................................................................
23
DOSAGE AND
ADMINISTRATION
..............................................................................................
29
OVERDOSAGE
...................................................................................................................................
31
ACTION AND CLINICAL PHARMACOLOGY
...............................................................................
32
STORAGE AND STABILITY
.............................................................................................................
35
DOSAGE FORMS, COMPOSITION AND PACKAGING
................................................................ 35
PART II: SCIENTIFIC INFORMATION
...........................................................................................
36
PHARMACEUTICAL INFORMATION
....................